Brief: Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation For Soft Tissue Sarcomas
20/01/2026 13:03
Jan 20 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA'S LP-284 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SOFT TISSUE SARCOMAS Source text: ID:nBw858hTTa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments